Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Foghorn Therapeutics Inc FHTX

Healthcare Biotechnology
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


NDAQ:FHTX - Post by User

Foghorn Therapeutics Inc
Bullboard Posts
Next >>
User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 2:03pm
59 Views
Post# 36161477

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Pioneering a New Cl

Foghorn Therapeutics Inc. (NASDAQ:FHTX): Pioneering a New Clhttps://beyondspx.com/2024/07/31/foghorn-therapeutics-inc-nasdaqfhtx-pioneering-a-new-class-of-precision-medicines-targeting-the-chromatin-regulatory-system/
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities